Pfizer: Citigroup maintains Neutral, raises PT to $26 from $25.

Pfizer: Citigroup maintains Neutral, raises PT to $26 from $25.

In a recent update, Citigroup has adjusted its price target for Pfizer Inc. (NYSE: PFE) to $26, up from the previous $25, while maintaining a Neutral rating on the pharmaceutical giant. This move follows a series of positive developments for the company, including recent earnings reports and policy updates in the biopharmaceutical sector.

Citigroup's analysts cited Pfizer's robust financial performance during the second quarter of 2025 as a key factor in the price target adjustment. The company reported earnings per share (EPS) of $0.78, which was significantly higher than the expected $0.57, marking a 36.84% surprise. Additionally, revenue exceeded expectations, reaching $14.7 billion compared to the anticipated $13.47 billion [1].

The investment firm also noted that Pfizer's guidance includes potential price changes this year based on recent policy developments, although the company provided limited details on the matter. This uncertainty led Citigroup to maintain a Neutral rating, reflecting a cautious approach to the stock's valuation.

Pfizer continues to navigate the evolving policy landscape in the pharmaceutical sector while managing investor expectations regarding potential pricing impacts on its business outlook. The company's strong financial performance and positive earnings announcements have garnered attention from various analysts, although no specific upgrades or downgrades have been mentioned in recent reports.

These updates provide valuable insights into Pfizer's financial health and market position, as investors closely watch these developments to assess the company's ongoing business strategies.

References:
[1] https://www.investing.com/news/analyst-ratings/morgan-stanley-raises-pfizer-stock-price-target-to-33-on-earnings-outlook-93CH-4171483